Fanny Chapelin

Dr. Fanny Chapelin

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2023 in Cells
Verified
Journal Article
Open access
PDF file
RGRoberto Gedaly
Roberto Gedaly
GOGabriel Orozco
Gabriel Orozco
AAAlexandre P. Ancheta
Alexandre P. Ancheta
MDMackenzie Donoho
Mackenzie Donoho
SDSiddharth N. Desai
Siddharth N. Desai
FMFRANCESC MARTI
FRANCESC MARTI
Background: Regulatory T cell (Treg) therapy is considered an alternative approach to induce tolerance in transplantation. If successful, this therapy may have implications on immunosuppression minimization/withdrawal to reduce drug-induced toxicity in patients. The aim of this study was to assess the efficacy of the mTORC1/C2 inhibitor, AZD8055, in the manufacturing of clinically competent Treg cells and compare the effects with those induced by rapamycin (RAPA), another mTOR inhibitor commonly used in Treg expansion protocols. Methods: Primary human Treg cells were isolated from leukapheresis product. Cell viability, expansion rates, suppressive function, autophagy, mitochondrial unfolded protein response (mitoUPR), and cell metabolic profile were assessed. Results: We observed a stronger inhibition of the mTORC2 signaling pathway and downstream events triggered by Interleukin 2 (IL2)-receptor in AZD8055-treated cells compared with those treated with RAPA. AZD8055 induced progressive metabolic changes in mitochondrial respiration and glycolytic pathways that disrupted the long-term expansion and suppressive function of Tregs. Unlike RAPA, AZD8055 treatment impaired autophagy and enhanced the mitoUPR cell stress response pathway. Conclusions: A distinct pattern of mTOR inhibition by AZD, compared with RAPA, induced mitochondrial stress response and dysfunction, impaired autophagy, and disrupted cellular bioenergetics, resulting in the loss of proliferative potential and suppressive function of Treg cells.

1 January 2021 in Radiology: Imaging Cancer
Verified
Journal Article
Closed access
FCFanny Chapelin
Fanny Chapelin
BLBenjamin I. Leach
Benjamin I. Leach
RCRuifeng Chen
Ruifeng Chen
DLDeanne Lister
Deanne Lister
KMKaren Messer
Karen Messer
EAEric T. Ahrens
Eric T. Ahrens
Fluorine 19 (19F) MRI enables temporal measurements of tumor cell oxygen tension in response to chimeric antigen receptor T-cell therapy; these data support the view that 19F partial pressure of ox... Purpose To assess the cell-specific, intracellular partial pressure of oxygen (Po2) dynamics of both tumor and chimeric antigen receptor (CAR) T cells in a murine immunotherapy model. Materials and...

21 October 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AKAman Khurana
Aman Khurana
FMFrancesc Marti
Francesc Marti
DPDavid K. Powell
David K. Powell
JBJ. Anthony Brandon
J. Anthony Brandon
ADAdam Dugan
Adam Dugan
FCFanny Chapelin
Fanny Chapelin
The success of several cell-based therapies and prevalent use of magnetic resonance imaging (MRI) in the clinic has fueled the development of contrast agents for specific cell tracking applications. Safe and efficient labeling of non-phagocytic cell types such as T cells nonetheless remains challenging. We developed a one-stop shop approach where the T cell sorting agent also labels the cells which can subsequently be depicted using non-invasive MRI. We compared the MR signal effects of magnetic-assisted cell sorting microbeads (CD25) to the current preclinical gold standard, ferumoxytol. We investigated in vitro labeling efficiency of regulatory T cells (Tregs) with MRI and histopathologic confirmation. Thereafter, Tregs and T cells were labeled with CD25 microbeads in vitro and delivered via intravenous injection. Liver MRIs pre- and 24 h post-injection were performed to determine in vivo tracking feasibility. We show that CD25 microbeads exhibit T2 signal decay properties similar to other iron oxide contrast agents. CD25 microbeads are readily internalized by Tregs and can be detected by non-invasive MRI with dose dependent T2 signal suppression. Systemically injected labeled Tregs can be detected in the liver 24 h post-injection, contrary to T cell control. Our CD25 microbead-based labeling method is an effective tool for Treg tagging, yielding detectable MR signal change in cell phantoms and in vivo. This novel cellular tracking method will be key in tracking the fate of Tregs in inflammatory pathologies and solid organ transplantation.

27 October 2021 in Molecular Imaging and Biology
Verified
Journal Article
Closed access
PDF file
FCFanny Chapelin
Fanny Chapelin
RGRoberto Gedaly
Roberto Gedaly
ZSZachary Sweeney
Zachary Sweeney
LGLiza J. Gossett
Liza J. Gossett

17 December 2023 in Cancers
Verified
Journal Article
Open access
PDF file
HYHarrison Yang
Harrison Yang
BHBrock Howerton
Brock Howerton
LBLogan Brown
Logan Brown
TITadahide Izumi
Tadahide Izumi
DCDennis Cheek
Dennis Cheek
FCFanny Chapelin
Fanny Chapelin
Background: Magnetic resonance imaging (MRI) is a non-invasive imaging modality which, in conjunction with biopsies, provide a qualitative assessment of tumor response to treatment. Intravenous injection of contrast agents such as fluorine (19F) nanoemulsions labels systemic macrophages, which can, then, be tracked in real time with MRI. This method can provide quantifiable insights into the behavior of tumor-associated macrophages (TAMs) in the tumor microenvironment and macrophage recruitment during therapy. Methods: Female mice received mammary fat pad injections of murine breast or colon cancer cell lines. The mice then received an intravenous 19F nanoemulsion injection, followed by a baseline 19F MRI. For each cancer model, half of the mice then received 8 Gy of localized radiation therapy (RT), while others remained untreated. The mice were monitored for two weeks for tumor growth and 9F signal using MRI. Results: Across both cohorts, the RT-treated groups presented significant tumor growth reduction or arrest, contrary to the untreated groups. Similarly, the fluorine signal in treated groups increased significantly as early as four days post therapy. The fluorine signal change correlated to tumor volumes irrespective of time. Conclusion: These results demonstrate the potential of 19F MRI to non-invasively track macrophages during radiation therapy and its prognostic value with regard to tumor growth.

6 November 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
RGRoberto Gedaly
Roberto Gedaly
GOGabriel Orozco
Gabriel Orozco
LLLillie J. Lewis
Lillie J. Lewis
DVDeepa Valvi
Deepa Valvi
FCFanny Chapelin
Fanny Chapelin
FMFRANCESC MARTI
FRANCESC MARTI
The manufacturing process of Regulatory T (Treg) cells for clinical application begins with the positive selection of CD25+ cells using superparamagnetic iron-oxide nanoparticle (SPION)-conjugated anti-CD25 antibodies (spCD25) and immunomagnetic cell separation technology. Our findings revealed that the interaction of spCD25 with its cell target induced the internalization of the complex spCD25-Interleukin-2 Receptor. Accumulation of intracellular spCD25 triggered oxidative stress, causing delayed Treg expansion and temporary reduction in suppressor activity. This activation delay hindered the efficient generation of clinically competent cells. During this early phase, Treg cells exhibited elevated mitochondrial superoxide and lipid peroxidation levels, with concomitant decrease on mitochondrial respiration rates. The results uncovered the increased mitochondrial unfolded protein response (mitoUPR). This protective, redox-sensitive activity is inherent of Tregs when contrasted with homologous, spCD25-treated, conventional T cells. While the temporary effects of spCD25 on clinically competent cells did not impede their use in a safety/feasibility pilot study with kidney transplant recipients*, it is reasonable to anticipate a potential reduction in their therapeutic efficacy. The mechanistic understanding of the adverse effects triggered by spCD25 is crucial for improving the manufacturing process of clinically competent Treg cells, a pivotal step in the successful implementation of immune cell therapy in transplantation. *Clinical trial registration number NCT03284242 at ClinicalTrials.gov.